(688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Report for Q3 2026
Filed with SSE · Stock code 688091 · · 12 pages · Chinese
Summary by 6ix AI
The report confirms that the financial statements have not been audited and includes significant financial data such as revenue and profit figures. It highlights a notable increase in research and development expenditures, reflecting ongoing investments in innovative drug development. The report also provides insights into shareholder information and the company's overall financial position as of the end of the reporting period.
Written in English by 6ix AI from the company’s Chinese-language filing. How 6ix writes summaries
Shanghai Yizhong Pharmaceutical Co. Ltd. on 6ix
Earlier from Shanghai Yizhong Pharmaceutical
- (688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Voluntary Disclosure of Completion of First Dosing in the First Dose Cohort of the Phase I Clinical Trial of Innovative Drug YXC-001
- (688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Implementation Results of Share Repurchase and Share Changes
- (688091)"Shanghai Yizhong Pharmaceutical Co., Ltd."Announcement on Progress in Repurchasing Shares
- Announcement on Participating in the 2026 Semi-annual Collective Performance Briefing for the STAR Market Innovative Drug Industry
- Announcement on the Grant of Reserved Restricted Shares to Participants under the 2026 Restricted Share Incentive Plan
Later from Shanghai Yizhong Pharmaceutical
All Shanghai Yizhong Pharmaceutical news releasesFollow Shanghai Yizhong Pharmaceutical into a list and get an email when it puts out news.
Follow Shanghai Yizhong Pharmaceutical